Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis.
|
|
- Elijah Clarke
- 5 years ago
- Views:
Transcription
1 Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. Supplementary online-material Supplementary Table S1: Detailed descriptive analysis regarding patient management Supplementary Table S2: Pre-selected variables and their definitions for the main analysis Supplementary Table S3: Definitions of SJS/TEN-specialised units and other dermatologic units per country 1
2 Supplementary Table S1: Detailed descriptive analysis regarding patient management other countries Overall n=120 n=263 n=59 n=442 treating unit 1 (frequency, percentage) dermatologic unit SJS/TEN-specialised unit thereof with prior stay on a dermatologic unit other unit (only) delay between onset of reaction and admission to (in days) (median, range) hospital (any unit) (n=442) dermatologic unit (n=178) (including patients further transferred) SJS/TEN-specialised unit (n=150) delay between admission to dermatologic unit and further transfer to specialised unit (n= 21) (median, range) therapies 2 (per drug) corticosteroids intraveus immuglobulins ciclosporin any other immumodulating drug 3 therapy combinations 2 (per patient) supportive therapy only corticosteroids only intraveus immuglobulins only ciclosporin only combination of drugs 4 33 (28%) 61 (51%) 4 ( 7%) 26 (22%) 102 (39%) 76 (29%) 17 (22%) 85 (32%) 22 (37%) 13 (22%) 0 ( 0%) 24 (41%) 157 (36%) 150 (34%) 21 (14%) 135 (31%) 3 (0-18) 2 (0-20) 2 (0-23) 2 (0-23) 4 (0-12) 4 (0-20) 4 (1-15) 4 (0-20) 5 (2-19) 5 (1-26) 7 (1-23) 5 (1-26) 3 (2-5) 2 (1-9) - 2 ( 1-9) 33 (28%) 249 (95%) 35 (59%) 317 (72%) 12 (10%) 52 (20%) 17 (29%) 81 (18%) 17 (14%) 1 ( 0%) 1 ( 2%) 19 ( 4%) 1 ( 1%) 4 ( 2%) 0 ( 0%) 5 ( 1%) 66 (55%) 12 ( 5%) 19 (32%) 97 (22%) 25 (21%) 196 (75%) 23 (39%) 244 (55%) 6 ( 5%) 2 ( 1%) 5 ( 8%) 13 ( 3%) 15 (12%) 0 ( 0%) 0 ( 0%) 15 ( 3%) 8 ( 7%) 53 (20%) 12 (20%) 73 (17%) 1 see supplementary table S3 for a description of variable definition 2 therapy: any immumodulating drug started at/after onset of reaction or, if administered before, when dosage/frequency was increased 3 any other immumodulating drug: daclizumab+etanercept (1), hydroxylcarbamide (1), infliximab (3) 4 combination of drugs: corticosteroids + 1 other immumodulating drug (68), corticosteroids + 2 other immumodulating drugs (5) 2
3 Supplementary Table S2: Pre-selected variables and their definitions for the main analysis variable (including explanation) levels missing values (%) 1 HR for death (95%CI) 2 country other countries 2.1 ( ) 2.1 ( ) age in years 4 ( ) (at time of reaction) gender male female 0.87 ( ) development of reaction (onset of reaction before hospitalisation, community in-hospital 2.6 ( ) onset of reaction during hospitalisation due to ather disease) severity of reaction (defined by the extent of skin detachment related to the body surface are: SJS <10%, SJS/TEN overlap 10-30%, TEN >30%) SJS SJS/TEN overlap TEN 2.1 ( ) 2.9 ( ) severe liver disorder [n=51] including liver dysfunction/failure [21], liver steatosis/cirrhosis [17], viral 3.1 ( ) hepatitis [8], tumour/metastases [3], amyloidosis [1], autoimmune liver disorders [1] severe kidney disorder [n=56] including (chronic) renal insufficiency/failure (including diabetic neuropathy) ( ) [45], acute renal failure (before onset of reaction) [9], amyloidosis [1], autoimmune kidney disorders [1] collagen-vascular disorder [n=27] 3 including rheumatoid arthritis [13], systemic lupus erythematosus [5], 0.99 ( ) systemic scleroderma [4], connective tissue disease [2], psoriasis arthropathica [2], ankylosing spondylitis [1], Morbus Wegener [1] recent malignancy [n=72] 4 diagsis of any malignant disorder diagsed within the last two years or ( ) still under treatment; including primary CNS tumours [13], urogenital cancer [13], hematologic malignancies [12], breast cancer [10], ENT carcima [6], lung cancer [6], gastrointestinal-tract cancer [5], cancer of unkwn primary [4], melama [3], sarcoma [2], Merkel cell carcima [1] HIV infection [n=20] (assuming HIV infection even if recent serology test was available) ( ) (continued) 3
4 recent infection [n=78] 5 present in 4 weeks before start of reaction, excluding long-lasting infections, n-severe/n-promoting infections, infections with start within 3 days before onset of the reaction; - respiratory tract infection [40] (including pneumonia, acute bronchitis, influenza/-like illness, infectious exacerbated COPD, pneumocystosis) - septicaemia, before onset of reaction [11] - CNS infection [8] (including cerebral toxoplasmosis, meningitis, ventriculitis) - miscellaneous infection [6] (including fever of unkwn origin) - tuberculosis [4] (including open, closed, and lymph de tuberculosis) - bone infection [3] (including coxitis, implant infection) - gastrointestinal infection [3] (including pseudomembraus colitis induced by clostridium difficile toxins, peritonitis) - heart infection [3] (including endocarditis) - viral infection [2] (including acute cytomegalovirus infection, infectious monucleosis) - ENT infection [1] (including ethmoiditis/spheiditis) - skin infection [1] (including psoas abscess) - urogenital infection [1] (including pyonephrosis) ( ) recent radiation therapy [n=36] (radiation therapy for any reason within the last three months) 1.7 ( ) prior steroid use [n=96] (steroid use in the week before onset) ( ) 1: proportion of missing values in follow-up cohort of 460 patients 2: univariable hazard ratios (HR) and 95% confidence interval (95%CI) based on complete case analysis 3: 1 patient had two different collagen-vascular disorders (rheumatoid arthritis+systemic lupus erythematosus) 4: 3 patients had recent malignancies at two different sites (breast+hematologic, breast+urogenital, hematologic+urogenital) 5: 5 patients had two infections CNS: central nervous system; ENT: ears, se, throat 4
5 Supplementary Table S3: Definitions of SJS/TEN-specialised units and other dermatologic units per country country SJS/TEN-specialised unit* dermatologic unit Austria any burn unit; any ICU at a university hospital any dermatologic unit any burn unit; dermatologic unit or ICU at the Hospital Henri Mondor, Creteil any burn unit; any ICU at a university hospital; any ICU with dermatologic consultation dermatologic unit at any hospital except Hospital Henri Mondor, Creteil any dermatologic unit Israel any ICU at a university hospital with dermatologic consultation any dermatologic unit Italy any burn unit; any ICU at a university hospital any dermatologic unit Netherlands any burn unit; dermatologic unit at the University Medical Center Groningen (UMCG); any unit with specialised supervision by UMCG dermatologic unit at any hospital except UMCG ICU: intensive care unit * SJS/TEN-specialised unit: In addition to the country-specific definition, 5 or more cases had to be treated in the unit over the whole study period in order to distinguish units with more practical experience from other units that only provide technical facility. 5
REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES. R e g i S C A R PATIENT'S DATA. Age country of birth
REGISTRY OF SEVERE CUTANEOUS ADVERSE REACTIONS TO DRUGS AND COLLECTION OF BIOLOGICAL SAMPLES R e g i S C A R PATIENT'S DATA Initials of the patient date of birth Age country of birth Gender male female
More informationRayos Prior Authorization Program Summary
Rayos Prior Authorization Program Summary FDA APPROVED INDICATIONS AND DOSAGE FDA-Approved Indications: 1 Agent Indication Dosage Rayos (prednisone delayedrelease tablet) as an anti-inflammatory or immunosuppressive
More informationHELPING YOU AND YOUR PATIENTS TALK OPENLY ABOUT MODERATELY TO SEVERELY ACTIVE RA
SIMPONI ARIA (golimumab) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) in combination with MTX, active psoriatic arthritis, and active ankylosing
More informationSupplementary materials for:
Supplementary materials for: Cecil E, Bottle A, Sharland M, Saxena S. Impact of UK primary care policy reforms on short-stay unplanned hospital admissions for children with primary care-sensitive conditions.
More informationWARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS
DECLESAU (dergrafloxacin) tablets, for oral use DECLESAU (dergrafloxacin) injection, solution for intravenous use WARNING: TENDON EFFECTS and EXACERBATION OF MYASTHENIA GRAVIS Fluoroquinolones, including
More informationUnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty
UnitedHealth Premium Physician Designation Program Episode Treatment Groups (ETG ) Description and Specialty 666700 Acne Family Medicine, Internal Medicine, Pediatrics 438300 Acute Bronchitis Allergy,
More informationLABETTE COMMUNITY COLLEGE BRIEF SYLLABUS. Please check with the LCC bookstore for the required texts for this class.
LABETTE COMMUNITY COLLEGE BRIEF SYLLABUS SPECIAL NOTE: This brief syllabus is not intended to be a legal contract. A full syllabus will be distributed to students at the first class session. TEXT AND SUPPLEMENTARY
More informationGOALS AND OBJECTIVES INFECTIOUS DISEASE
GOALS AND OBJECTIVES INFECTIOUS DISEASE Infectious Disease and HIV Overview: The Infectious Diseases Program at the University of Southern California prepares trainees for the management of problems in
More informationSupplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Jain S, Kamimoto L, Bramley AM, et al. Hospitalized patients
More informationLahey Clinic Internal Medicine Residency Program: Curriculum for Infectious Disease
Lahey Clinic Internal Medicine Residency Program: Curriculum for Infectious Disease Faculty representative: Eva Piessens, MD, MPH Resident representative: Karen Ganz, MD Revision date: February 1, 2006
More informationPre-Admission Testing Questionnaire
Pre-Admission Testing Questionnaire Approximately 2 weeks prior to your surgery date you will receive a telephone call from our Pre-Admission Testing department. During this conversation, a Registered
More informationList of Qualifying Conditions
List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rayos) Reference Number: CP.CPA.273 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationICD-9-CM CODING FUNDAMENTALS CODING EXERCISES
Steps to Accurate Coding Underline the main term, then locate code: Stenosis of Carotid Artery Transient Ischemic Attack Gastrointestinal hemorrhage Degenerative Joint Disease Coronary Artery Disease Alcoholic
More informationRisk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohor t study
Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohor t study BMJ 2017; 356 doi: https://doi.org/10.1136/bmj.j895 (Published
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL efigures efigure: Standardised differences between TNF-α inhibitor users and non-users before and after matching on fixed factors and propensity scores. etables etable 1: All diagnoses
More informationWhat prescribers need to know
HUMIRA Citrate-free presentations in an Electronic Medical Record (EMR) What prescribers need to know 2 / This is your guide to identifying HUMIRA Citrate-free presentations in your Electronic Medical
More informationLECOM Health Ophthalmology
Patient Name: Date of Birth: New Patient Questionnaire Your answers will be used by your healthcare provider get an accurate history of your medical conditions and ocular concerns. If you are uncomfortable
More informationNurseAchieve. CHAPTERS INCLUDED IN THE NURSEACHIEVE COMPREHENSIVE NCLEX REVIEW NURSING SKILLS AND FUNDAMENTALS:
NurseAchieve www.nurseachieve.com CHAPTERS INCLUDED IN THE NURSEACHIEVE COMPREHENSIVE NCLEX REVIEW NCLEX TEST STRATEGIES: NCLEX EXAM OVERVIEW TEST TAKING STRATEGIES NURSING SKILLS AND FUNDAMENTALS: ADMINISTRATION
More informationAntimicrobial Stewardship in Community Acquired Pneumonia
Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis
More informationNew Patient Paperwork
New Patient Paperwork Date: Phone: Patient: Last Name First Name Initial Street Address: City/State/Zip Code: Sex: M F Age: Birthdate: Single Married Widowed Separated Divorced Email: Newsletter? Y N Insured
More informationTexas Prior Authorization Program Clinical Edit Criteria. H.P. Acthar
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationInternal Medicine Certification Examination Blueprint
Internal Medicine Certification Examination Blueprint What Does the Examination Cover? The exam is designed to evaluate the extent of the candidate s knowledge and clinical judgment in the areas in which
More informationPRIOR AUTHORIZATION REQUEST GUIDE
PRIOR AUTHORIZATION REQUEST GUIDE Drafting a Prior Authorization Request The following information is presented for informational purposes only and is not intended to provide reimbursement or legal advice.
More informationSevere β-lactam allergy. Alternative (use for mild-moderate β-lactam allergy) therapy
Recommended Empirical Antibiotic Regimens for MICU Patients Notes: The antibiotic regimens shown are general guidelines and should not replace clinical judgment. Always assess for antibiotic allergies.
More informationEpisodes of Care Risk Adjustment
Episodes of Care Risk Adjustment Episode Types Wave 1 Asthma Acute Exacerbation Perinatal Total Joint Replacement Wave 2 Acute Percutaneous Coronary Intervention COPD Acute Exacerbation Non-acute Percutaneous
More informationDATE OF BIRTH: MELANOMA INTAKE
MELANOMA INTAKE GENERAL INFORMATION How was your first diagnosed? (Check the diagnosis that describes your condition.) Melanoma Merkel Cell Carcinoma Squamous Cell Carcinoma Basal Cell Carcinoma Other
More informationAppendix 1: Supplementary tables [posted as supplied by author]
Appendix 1: Supplementary tables [posted as supplied by author] Table A. International Classification of Diseases, Ninth Revision, Clinical Modification Codes Used to Define Heart Failure, Acute Myocardial
More informationLondon, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8
London, 1 June 2006 Product name: REMICADE Procedure number: Remicade-H-240-II-73-AR SCIENTIFIC DISCUSSION 1/8 1. Introduction Infliximab is a chimeric human-murine IgG1κ monoclonal antibody, which binds
More informationName: (Last), (First), (Middle) Date of Birth: SS: Left or Right Handed: Complete Address: Phone: Home: Cell: Work:
An Outpatient Department of PLEASE FILL OUT ALL INFORMATION COMPLETELY Date Completed Name: (Last), (First), (Middle) Date of Birth: SS: Left or Right Handed: Complete Address: Phone: Home: Cell: Work:
More informationInvasive Bacterial Disease
Invasive Bacterial Disease Neisseria meningitidis, Haemophilus influenzae, and Group B Streptococcus (Streptococcus agalactiae) Case Report Form Electronic Disease Surveillance System Division of Surveillance
More informationTable of Contents. Course CME Credits. General Principles Topic CME Credit(s)
Table of Contents Course Course CME Credits Med-Challenger SPEX Comprehensive Review 266.0 CME Credits General Principles 21.0 CME Credit(s) Abdominal Pain 1.0 Acute Pelvic Pain in Women 1.0 Acute Vaginal
More informationAgeing and the burden of diseases in the elderly. Karl-Heinz Krause Geneva University Hospitals and Medical Faculty
Ageing and the burden of diseases in the elderly Karl-Heinz Krause Geneva University Hospitals and Medical Faculty - Norwegian Surveillance System for Communicable Diseases (MSIS) - Clinicians and laboratories
More informationAnswer Key: ARS Questions Presented in Live Course Presentations (Non Board Review or Photo Opportunity)
Answer Key: ARS Questions Presented in Live Course Presentations (Non Board Review or Photo Opportunity) Contents Volume I... 2 Online Only Lectures... 2 Saturday, August 24, 2013 (Lectures 1 10)... 3
More informationDERMATOLOGICAL EMERGENCIES. DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE
DERMATOLOGICAL EMERGENCIES DR. Ian Hoyle MBBS DIP IMC RCS (Ed), DA (UK),FRACGP,FACRRM,DIP DERM(Wales) TASMANIAN SKIN AND BODY CENTRE Dermatological Emergencies INFECTIONS ERYTHRODERMA DRUG ERUPTIONS STEVENS-JOHNSON
More informationManagement of Immune Reconstitution Inflammatory Syndrome (IRIS)
Management of Immune Reconstitution Inflammatory Syndrome (IRIS) Adult Clinical Guideline from the New York State Department of Health AIDS Institute www.hivguidelines.org Purpose of the IRIS Guideline
More informationMEDICAL HISTORY FORM FOR FOLLOW-UP
MEDICAL HISTORY FORM FOR FOLLOW-UP ID NUMBER: 0a) Form Date... / / 0b) Staff Code... Instructions: Whenever numerical responses are required, enter the number so that the last digit appears in the rightmost
More informationPharmacy Prep. Qualifying Pharmacy Review
Pharmacy Prep 2014 Misbah Biabani, Ph.D Director, Tips Review Centres 5460 Yonge St. Suites 209 & 210 Toronto ON M2N 6K7, Canada Luay Petros, R.Ph Pharmacy Manager, Wal-Mart, Canada 1 Disclaimer Your use
More informationPast Medical History. Chief Complaint: Patient Name: Appointment Date: Page 1
Appointment Date: Page 1 Chief Complaint: (Please write reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History PERSONAL SKIN HISTORY YES NO Yes - Details Melanoma
More informationIn your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed.
Name: SS# In your own words, please write the reason you are here. Please be specific, putting in dates as necessary. Use the back of the form if needed. Patient Medical, Surgical and Family History Review
More informationESCMID Online Lecture Library. by author
Therapies or diseases predisposing to infection Congenital immunodeficiences Acquired conditions Common variable immunedeficiency particular diseases (e.g. HIV, cancer,leukemia, lymphoma, diabetes, cystic
More informationPremium Specialty: Pediatrics
Premium Specialty: Pediatrics Credentialed Specialties include: Adolescent Medicine, Pediatric Adolescent, and Pediatrics This document is designed to be used in conjunction with the UnitedHealth Premium
More informationCUMULATIVE ILLNESS RATING SCALE (CIRS)
CUMULATIVE ILLNESS RATING SCALE (CIRS) The CIRS used in this protocol is designed to provide an assessment of recurrent or ongoing chronic comorbid conditions, classified by 14 organ systems. Using the
More informationPATIENT INFORMATION. Last Name First Name MI. Address. City State Zip. Cell Phone _( ) Home Phone _( ) May we contact you by ?
PATIENT INFORMATION date: Last Name First Name MI Address City State Zip Cell Phone _( ) Home Phone _( ) Email May we contact you by email? Yes No Date of Birth Age Marital Status Patient s Occupation
More informationAdvanced HIV and seriously ill: challenges in low resource settings Rosie Burton, Southern African Medical Unit, MSF
Advanced HIV and seriously ill: challenges in low resource settings Rosie Burton, Southern African Medical Unit, MSF Mozambique Mozambique Mozambique Mozambique Preventing mortality MSF hospital, Kinshasa,
More informationIMPACT #: Local Inventory #: form 04. Age at admission: d. mo yr. Postal code:
- Date of birth: birth: Date of admission: year month day year month day Age at admission: d mo yr Postal code: Ethnic code: Hospital: Gender: 1 = male 2 = female 1 = Impact 2 = Other local, specify: Code
More informationEASTERN ARIZONA COLLEGE Human Pathophysiology
EASTERN ARIZONA COLLEGE Human Pathophysiology Course Design 2016-2017 Course Information Division Allied Health Course Number HCE 240 Title Human Pathophysiology Credits 4 Developed by Dr. Robert Richman
More informationHu J, Gonsahn MD, Nerenz DR. Socioeconomic status and readmissions: evidence from an urban teaching hospital. Health Aff (Millwood). 2014;33(5).
Appendix Definitions of Index Admission and Readmission Definitions of index admission and readmission follow CMS hospital-wide all-cause unplanned readmission (HWR) measure as far as data are available.
More informationSTUDENT MEDICATIONS If your child is accepted, he or she must bring all prescription medications in their original pharmacy container.
TEXAS SCHOOL FOR THE BLIND AND VISUALLY IMPAIRED STUDENT MEDICAL / DIETARY HISTORY FORM Information for Parent: So that we can safely care for your child, please provide complete and specific information
More informationVasculitis and Vasculitides. OMONDI OYOO Physician/Rheumatologist; Senior Lecturer, Department of Medicine University of Nairobi
Vasculitis and Vasculitides OMONDI OYOO Physician/Rheumatologist; Senior Lecturer, Department of Medicine University of Nairobi Definition Presence of leucocytes in the vessel wall with reactive damage
More informationPast Medical History. Chief Complaint: Appointment Date: Page 1
Appointment Page 1 Chief Complaint: (reason, symptoms, condition or diagnosis that prompts your appointment) Past Medical History EYES Yes No Yes Details Glaucoma EAR, NOSE AND THROAT Hearing difficulty
More informationPUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: , VERSION 1
PUBLIC SUMMARY OF RISK MANAGEMENT PLAN BURANA 40 MG/ML ORAL SUSPENSION DATE: 15-5-2015, VERSION 1 VI.2 Elements for a Public Summary VI.2.1 Overview of disease epidemiology Musculoskeletal pain: Musculoskeletal
More informationTreatment of febrile neutropenia in patients with neoplasia
Treatment of febrile neutropenia in patients with neoplasia George Samonis MD, PhD Medical Oncologist Infectious Diseases Specialist Professor of Medicine The University of Crete, Heraklion,, Crete, Greece
More informationCreighton University Internal Medicine Residency Curriculum Cycle of 33 months
Creighton University Internal Medicine Residency Curriculum Cycle of 33 months Cardiology: 13 lectures and once a month EKG lecture, 25 total 1. EKG interpretation Once a month 2. Heart failure: 2 lectures.
More informationAnnouncing HUMIRA. Psoriasis Starter Package
Announcing HUMIRA (adalimumab) Psoriasis Starter Package HUMIRA is indicated for the treatment of adult patients with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy
More informationCENTRAL COAST ORTHOPEDIC MEDICAL GROUP Medical History Questionnaire GENERAL INFORMATION
GENERAL INFORMATION Last Name: First Name: What name do you prefer to be called? Age: DOB: / / Height: Weight: Left or Right Handed : Right Left Marital Status: M S D W Name of spouse or significant other:
More informationComplications after HSCT. ICU Fellowship Training Radboudumc
Complications after HSCT ICU Fellowship Training Radboudumc Type of HSCT HSCT Improved outcome due to better HLA matching, conditioning regimens, post transplant supportive care Over one-third have pulmonary
More informationInterQual Level of Care 2018 Index
InterQual Level of Care 2018 Index Rehabilitation Criteria Index Words by Subset The Index is an alphabetical listing of conditions and/or diagnoses designed to guide the user to the criteria subset where
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Blum CA, Nigro N, Briel M, et al. Adjunct prednisone
More informationINFECTIOUS DISEASES IN THE LONG TERM CARE FACILITY
INFECTIOUS DISEASES IN THE LONG TERM CARE FACILITY The following is a list of the most common infectious diseases that are to be found in the long term care facility. Precautions are recommended and the
More informationKEYTRUDA is also indicated in combination with pemetrexed and platinum chemotherapy for the
FDA-Approved Indication for KEYTRUDA (pembrolizumab) in Combination With Carboplatin and Either Paclitaxel or Nab-paclitaxel for the Firstline Treatment of Patients With Metastatic Squamous Non Small Cell
More informationWhat is Enbrel? Key features
What is Enbrel? Enbrel (also known by its generic name etanercept) is a biologic medication approved in April 2004 by the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe
More informationCONTENT OUTLINE FOR THE PHARMACOTHERAPY CERTIFICATION EXAMINATION
CONTENT OUTLINE FOR THE PHARMACOTHERAPY CERTIFICATION EXAMINATION The following domains, tasks and knowledge statements were delineated by the BPS Specialty Council on Pharmacotherapy and validated through
More informationPrioritized ShortList MORBIDITY
Report on in-depth analysis of pilot studies in 16 Member States on diagnosis-specific morbidity statistics Annex 2 (Rev 11_11_13) Prioritized ShortList MORBIDITY Legend: X recommended for collection Y
More informationThe legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 3 October 2012
The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 3 October 2012 REMICADE 100 mg, powder for concentrate for solution for infusion B/1 vial (CIP code: 562 070-1) Applicant:
More informationDilantin (phenytoin) ROBERT A. SCHWARTZ
Dilantin (phenytoin) ROBERT A. SCHWARTZ Bailey & Galyen Attorney in Charge, Mass Tort Litigation Managing Attorney, Houston 18333 Egret Bay Blvd., Suite 120 Houston, Texas 77058 Toll Free: (866) 715-1529
More informationSecondary Immunodeficiency
A guide for patients, their families, friends and healthcare professionals Raising awareness and supporting patients with immunodeficiencies in Australia. Secondary Immunodeficiency Edition 1 Date 15 th
More informationTABLE I-1: RESIDENT INFANT DEATHS PER 1,000 LIVE BIRTHS, BY RACE AND ETHNICITY, FLORIDA AND UNITED STATES, CENSUS YEARS AND
TABLE I-1: RESIDENT INFANT DEATHS PER 1,000 LIVE BIRTHS, BY RACE AND ETHNICITY, FLORIDA AND UNITED STATES, CENSUS YEARS 1970-2000 AND 2004-2014 FLORIDA 1 UNITED STATES 1 YEAR WHITE2 BLACK2 HISPANIC3 WHITE2
More informationHumira. (adalimumab) Drug Update Slideshow NEW INDICATION
Humira (adalimumab) NEW INDICATION Drug Update Slideshow Introduction Brand name: Humira Generic name: Adalimumab Pharmacological class: Tumor necrosis factor (TNF) blocker Strength and Formulation: 10mg/0.2mL,
More informationMANAGEMENT OF SUSPECTED VIRAL ENCEPHALITIS IN CHILDREN
MANAGEMENT OF SUSPECTED VIRAL ENCEPHALITIS IN CHILDREN OVERVIEW 1980s: dramatically improved by aciclovir HSV encephalitis in adults Delays treatment(> 48h after hospital admission): associated with a
More informationKey uncertainties around the evidence or technology are that the test has only been validated in biochemical studies.
pat hways PredictSure-IBD for inflammatory bowel disease prognosis Medtech innovation briefing Published: 25 March 2019 nice.org.uk/guidance/mib178 Summary The technology described in this briefing is
More informationSYNOPSIS. Clinical Study Report IM Double-blind Period
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Abatacept () Name of Active Ingredient: Abatacept () Individual Study Table Referring to the Dossier SYNOPSIS (For National Authority
More informationClinialTrials.gov Identifier: sanofi-aventis. Sponsor/company: 07/November/2008
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription Sponsor/company: sanofi-aventis ClinialTrials.gov
More informationImmunosuppressants. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia
Immunosuppressants Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia Immunosuppressive Agents Very useful in minimizing the occurrence of exaggerated or inappropriate
More informationPolmoniti: Steroidi sì, no, quando. Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma
Polmoniti: Steroidi sì, no, quando Alfredo Chetta Clinica Pneumologica Università degli Studi di Parma Number of patients Epidemiology and outcome of severe pneumococcal pneumonia admitted to intensive
More informationDRG Code DRG Description FY18 Average Charge
DRG Code DRG Description FY18 Average Charge 3 ECMO OR TRACH W MV 96+ HRS OR PDX EXC FACE, MOUTH & NECK W MAJ O $ 665,511 4 TRACH W MV 96+ HRS OR PDX EXC FACE, MOUTH & NECK W/O MAJ O.R. $ 422,497 37 EXTRACRANIAL
More informationCELEBRATING 169 YEARS OF TRADITION AND TRANSFORMATION IN HEALTHCARE RESEARCH
CELEBRATING 169 YEARS OF TRADITION AND TRANSFORMATION IN HEALTHCARE RESEARCH Our MISSION Building on our tradition Reaching out to the community Doing our best to serve, care and heal Together, we aim
More informationImmunotherapy Treatment Developments in Medical Oncology
Immunotherapy Treatment Developments in Medical Oncology A/Prof Phillip Parente Director Cancer Services Eastern Health Executive MOGA ATC Medical Oncology RACP www.racpcongress.com.au Summary of The Desired
More informationPATIENT HISTORY QUESTIONNAIRE
PATIENT HISTORY QUESTIONNAIRE The information requested in this questionnaire is very important. To give you the best care and to obtain your insurance approval, we must have complete answers. If you are
More informationPART III: CONSUMER INFORMATION
PART III: CONSUMER INFORMATION Pr INFLECTRA (infliximab for Injection) INFLECTRA is a subsequent entry biologic (SEB) to REMICADE. An SEB is a biologic drug product that is authorized based on its likeness
More informationElements for a Public Summary
VI.2 VI.2.1 Elements for a Public Summary Overview of disease epidemiology Rapenin (phenoxymethylpenicillin potassium) is indicated for the treatment of infections caused by penicillin-sensitive bacteria.
More informationSupplementary Online Content
Supplementary Online Content Lee C-C, Lee M-tG, Chen Y-S. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Internal Medicine. Published online October 5, 2015.
More informationSCIENTIFIC DISCUSSION
European Medicines Agency London, 20 September 2007 Product name: Remicade Procedure number: EMEA/H/C/240/II/95 SCIENTIFIC DISCUSSION 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20)
More informationMONTEFIORE MEDICAL CENTER TRANSPLANT PROGRAM LIVING DONOR EVALUATION FORM History Questionnaire
MONTEFIORE MEDICAL CENTER TRANSPLANT PROGRAM LIVING DONOR EVALUATION FORM History Questionnaire Donor s Name: Today s Date: Social Security #: Date of Birth Age Sex Address: Telephone #: (home) (work)
More informationPAEDIATRIC Point Prevalence Survey. Ward Form
Appendix 1 PAEDIATRIC Point Prevalence Survey Ward Form Please fill in one form for each ward included in PPS Date of survey Person completing form (Auditor code) Hospital Name Department/Ward Paediatric
More informationPharmacotherapy Handbook
Pharmacotherapy Handbook Eighth Edition Barbara G. Wells, PharmD, HP, FCCP, BCPP Dean and Professor Executive Director, Research Institute of Pharmaceutical Sciences School of Pharmacy, The University
More informationNEOFEN 60 mg suppository
PACKAGE LEAFLET: INFORMATION FOR THE USER NEOFEN 60 mg suppository IBUPROFEN This leaflet is a copy of the Summary of Product Characteristics and Patient Information Leaflet for a medicine, which outlines
More informationLongevitology Toronto Canada Questions. A: Two compulsory questions: B: 102 Questions
Longevitology Toronto Canada - 102 Questions A: Two compulsory questions: What is Longevitology? Longevitology is the knowledge to receive the cosmic energy so as to strengthen the Chi in human body, thus
More informationInterQual Level of Care 2018 Index
InterQual Level of Care 2018 Index Long-Term Acute Care (LTAC) Criteria The Index is an alphabetical listing of conditions and/or diagnoses designed to guide the user to the criteria subset where a specific
More informationDiagnosis-specific morbidity - European shortlist
I Certain infectious and parasitic diseases 1 Tuberculosis A15-A19 X X Z 2 Sexually transmitted diseases (STD) A50-A64 Y Z 3 Viral hepatitis (incl. hepatitis B) B15-B19 X Z 4 Human immunodeficiency virus
More informationMEDICAL ASSESSMENT PART 1 - SOCIAL HISTORY
Smoking history Alcohol history Never Quit Never Quit PART 2 - MEDICAL HISTORY Date of last colonoscopy? Date of last mammogram? Date of last pap smear? Date of last flu vaccine? Date of last pneumonia
More informationSelected tables standardised to Segi population
Selected tables standardised to Segi population LIST OF TABLES Table 4.2S: Selected causes of death, all-ages, 2000 2004 (Segi Standard) Table 5.3S: Public hospitalisations by major cause of admission
More informationMEDICAL HISTORY FORM FOR FOLLOW-UP
MEDICAL HISTORY FORM FOR FOLLOW-UP ID NUMBER: 0a) Date of Collection / / 0b) Staff Code Instructions: Whenever numerical responses are required, enter the number so that the last digit appears in the rightmost
More informationWe will review the need for continuing treatment with you after 3 months and again after one year.
Patient Information Drugs for Inflammatory Bowel Disease Adalimumab (Humira) Clinical Nurse Specialist - Allyson Lewis Clinical Nurse Specialist Gareth Lloyd-Ford Clinical Nurse Specialist Lynsey Hook
More informationAUTOIMMUNE DISORDERS IN THE ACUTE SETTING
AUTOIMMUNE DISORDERS IN THE ACUTE SETTING Diagnosis and Treatment Goals Aimee Borazanci, MD BNI Neuroimmunology Objectives Give an update on the causes for admission, clinical features, and outcomes of
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Williams CM, Maher CG, Latimer J, et al. Efficacy
More informationFever in Lupus. 21 st April 2014
Fever in Lupus 21 st April 2014 Fever in lupus Cause of fever N= 487 % SLE fever 206 42 Infection in SLE 265 54.5 Active SLE and infection 8 1.6 Tumor fever 4 0.8 Miscellaneous 4 0.8 Crucial Question Infection
More informationtudiesofl.e. Factor and Related Anti-nuclear Serum Factors in Rheumatoid Arthritis and Liver Cirrhosis
S tudiesofl.e. Factor and Related Anti-nuclear Serum Factors in Rheumatoid Arthritis and Liver Cirrhosis Masafumi KOMIYA The Second Department of Internal Medicine (Prof. H. Ueda) Faculty of Medicine,
More informationPLEASE COMPLETE ALL SECTIONS OF THIS FORM
PLEASE COMPLETE ALL SECTIONS OF THIS FORM Patient Name: Date of Birth: Referring Doctor? (Name, telephone number and address) Chief Complaint: Why have you come here? How did it start? What are the symptoms?
More informationDRAFT. Remission rates, calculated using observed case (OC) analyses were as follows: Year 1 Year 2 Year 3 Year 4 All patients 62.
DRAFT New Efficacy Data Shows Cimzia (certolizumab pegol) Provides Long-Term Remission of Moderate to Severe Crohn s Disease Regardless of Prior Anti-TNF Exposure, According to Data Presented at DDW Oral
More information